2014
Leptin reverses diabetes by suppression of the hypothalamic-pituitary-adrenal axis
Perry RJ, Zhang XM, Zhang D, Kumashiro N, Camporez JP, Cline GW, Rothman DL, Shulman GI. Leptin reverses diabetes by suppression of the hypothalamic-pituitary-adrenal axis. Nature Medicine 2014, 20: 759-763. PMID: 24929951, PMCID: PMC4344321, DOI: 10.1038/nm.3579.Peer-Reviewed Original Research
1998
Efficacy and Metabolic Effects of Metformin and Troglitazone in Type II Diabetes Mellitus
Inzucchi S, Maggs D, Spollett G, Page S, Rife F, Walton V, Shulman G. Efficacy and Metabolic Effects of Metformin and Troglitazone in Type II Diabetes Mellitus. New England Journal Of Medicine 1998, 338: 867-873. PMID: 9516221, DOI: 10.1056/nejm199803263381303.Peer-Reviewed Original ResearchConceptsEndogenous glucose productionPlasma glucose concentrationPostprandial plasma glucose concentrationsPeripheral glucose disposalType 2 diabetesMetformin therapyTroglitazone therapyGlucose disposalGlucose productionHemoglobin valuesGlucose concentrationType II diabetes mellitusAdditive beneficial effectsSingle-drug therapyDiabetes mellitusGlycemic controlCombination therapyPoor responseMetabolic effectsPhysiologic effectsMetforminPatientsTherapyTroglitazoneBeneficial effects
1982
Implantable Insulin Infusion Devices
Blackshear P, Nathan D, Cohen A, Hurxthal K, Shulman G. Implantable Insulin Infusion Devices. JAMA 1982, 248: 2111-2111. PMID: 7120635, DOI: 10.1001/jama.1982.03330170019006.Peer-Reviewed Original ResearchConceptsInsulin infusion devicesInfusion devicesSimilar glycemic controlIntensive conventional therapyImplantation of devicesGlycemic controlSubstantial morbidityConventional therapyInsulin delivery systemsAnimal studiesClinical useDelivery systemLong-term studiesImplantable drug delivery systemsResearch protocolDrug delivery systemsExtreme cautionImplantationMorbidityTherapyMortality